ROCHE, Confidence Building up on Next Gen. Rituxan (GA101) - new market research report published
Rituxan - a new market research report on companiesandmarkets.com Roche seems to be on track of delivering sustainable growth as it announced today that Obinutuzumab , follow-on biologic to Rituxan has demonstrated significant improvement of PFS against chemotherapy in first-line CLL in the first PhIII study.
New Immunoglobulins Study Findings Have Been Reported by F. Cameron and Co-Researchers
It is approved in the US for use in combination with chlorambucil for the first-line treatment of chronic lymphocytic leukaemia , and has been filed for approval in the EU in this indication."
New Drug and Biological Product Approvals, 2013
Manufacturers can request breakthrough therapy designation for products that target serious or life-threatening illness and are expected, on the basis of preliminary clinical evidence, to offer substantial benefits over existing treatments.
New Drug Combo Might Help Older, Sicker Patients With Leukemia
The research, led by German scientists, included nearly 800 older people who had been diagnosed with chronic lymphocytic leukemia.